Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TEMOkids Study: A Population Pharmacokinetic, Acceptability and Safety Study for KIMOZO, a Paediatric Oral Suspension of Temozolomide

NCT04610736 is registered in ClinicalTrials.gov with Orphelia Pharma as lead sponsor.

NCT NCT04610736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04610736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TEMOkids Study: A Population Pharmacokinetic, Acceptability and Safety Study for KIMOZO, a Paediatric Oral Suspension of Temozolomide
Lead sponsor
Orphelia Pharma
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2021
Completion date
July 3, 2023
Enrollment
49 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric cancer